Fracture Risks in Patients Treated With Different Oral Anticoagulants: A Systematic Review and Meta-Analysis.

Huei‐Kai Huang,Carol Chiung‐Hui Peng,Shu‐Man Lin,Kashif M. Munir,Rachel Huai‐En Chang,Brian Bo‐Chang Wu,Peter Pin‐Sung Liu,Jin‐Yi Hsu,Ching‐Hui Loh,Yu‐Kang Tu

DOI: https://doi.org/10.1161/jaha.120.019618

IF: 6.106

2021-03-25

Journal of the American Heart Association

Abstract:Background Evidence on the differences in fracture risk associated with non‐vitamin K antagonist oral anticoagulants (NOAC) and warfarin is inconsistent and inconclusive. We conducted a systematic review and meta‐analysis to assess the fracture risk associated with NOACs and warfarin. Methods and Results We searched PubMed, Embase, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov from inception until May 19, 2020. We included studies presenting measurements (regardless of primary/secondary/tertiary/safety outcomes) for any fracture in both NOAC and warfarin users. Two or more reviewers independently screened relevant articles, extracted data, and performed quality assessments. Data were retrieved to synthesize the pooled relative risk (RR) of fractures associated with NOACs versus warfarin. Random‐effects models were used for data synthesis. We included 29 studies (5 cohort studies and 24 randomized controlled trials) with 388 209 patients. Patients treated with NOACs had lower risks of fracture than those treated with warfarin (pooled RR, 0.84; 95% CI, 0.77–0.91; P <0.001) with low heterogeneity ( I 2 =38.9%). NOACs were also associated with significantly lower risks of hip fracture than warfarin (pooled RR, 0.89; 95% CI, 0.81–0.98; P =0.023). A nonsignificant trend of lower vertebral fracture risk in NOAC users was also observed (pooled RR, 0.74; 95% CI, 0.54–1.01; P =0.061). Subgroup analyses for individual NOACs demonstrated that dabigatran, rivaroxaban, and apixaban were significantly associated with lower fracture risks. Furthermore, the data synthesis results from randomized controlled trials and real‐world cohort studies were quite consistent, indicating the robustness of our findings. Conclusions Compared with warfarin, NOACs are associated with lower risks of bone fracture. Nonstandard Abbreviations and Acronyms NOAC non‐vitamin K antagonist oral anticoagulant OAC oral anticoagulant Clinical Perspective What Is New? This systematic review and meta‐analysis gathered data from 388 209 participants in 29 studies and showed that patients taking non‐vitamin K antagonist oral anticoagulants had an overall 16% lower risk of developing fractures compared with those taking warfarin. Subgroup analyses for individual non‐vitamin K antagonist oral anticoagulants demonstrated that dabigatran, rivaroxaban, and apixaban were significantly associated with lower fracture risks. The evidence from real‐world cohort studies and randomized controlled trials is quite consistent, indicating the robustness of our findings. What Are the Clinical Implications? This meta‐analysis provided up‐to‐date evidence showing that non‐vitamin K antagonist oral anticoagulants may be the preferred alternatives to warfarin for lowering fracture risks in patients requiring oral anticoagulant therapy. Oral anticoagulants (OACs) are commonly prescribed to prevent or treat thromboembolic events in patients with atrial fibrillation or venous thromboembolism. 1 , 2 Warfarin, a vitamin K antagonist, is a traditional OAC and has been a primary long‐term treatment option for patients with atrial fibrillation or venous thromboembolism for decades. Recently, non‐vitamin K antagonist oral anticoagulants (NOACs) have been approved as alternatives to vitamin K antagonists and have demonstrated similar or superior efficacy and safety compared with warfarin. 3 , 4 Because aging is one of the strongest risk factors for both atrial fibrillation and venous thromboembolism, 5 , 6 the prescription of OACs has gradually increased in the aging population worldwide. Some previous studies have suggested that warfarin may increase fracture risks via its vitamin K antagonizing effect, which impairs bone mineralization; in contrast, NOACs are independent of mechanisms associated with vitamin K antagonists. However, previous studies have -Abstract Truncated-

cardiac & cardiovascular systems